- Home
- CRDF vs TLSI Comparison
CRDF vs TLSI Comparison
Compare CRDF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- TLSI
- Stock Information
- Founded
- CRDF 1999
- TLSI 2010
- Country
- CRDF United States
- TLSI United States
- Employees
- CRDF N/A
- TLSI N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- TLSI Medical Specialities
- Sector
- CRDF Health Care
- TLSI Health Care
- Exchange
- CRDF Nasdaq
- TLSI Nasdaq
- Market Cap
- CRDF 195.6M
- TLSI 160.4M
- IPO Year
- CRDF N/A
- TLSI N/A
- Fundamental
- Price
- CRDF $2.85
- TLSI $5.74
- Analyst Decision
- CRDF Strong Buy
- TLSI Strong Buy
- Analyst Count
- CRDF 4
- TLSI 6
- Target Price
- CRDF $12.00
- TLSI $11.75
- AVG Volume (30 Days)
- CRDF 1.6M
- TLSI 57.4K
- Earning Date
- CRDF 05-01-2025
- TLSI 05-14-2025
- Dividend Yield
- CRDF N/A
- TLSI N/A
- EPS Growth
- CRDF N/A
- TLSI N/A
- EPS
- CRDF N/A
- TLSI N/A
- Revenue
- CRDF $683,000.00
- TLSI $29,431,000.00
- Revenue This Year
- CRDF N/A
- TLSI $55.95
- Revenue Next Year
- CRDF N/A
- TLSI $52.21
- P/E Ratio
- CRDF N/A
- TLSI N/A
- Revenue Growth
- CRDF 39.96
- TLSI 58.99
- 52 Week Low
- CRDF $2.01
- TLSI $3.50
- 52 Week High
- CRDF $5.64
- TLSI $10.24
- Technical
- Relative Strength Index (RSI)
- CRDF 41.85
- TLSI 59.91
- Support Level
- CRDF $2.36
- TLSI $5.23
- Resistance Level
- CRDF $3.04
- TLSI $5.66
- Average True Range (ATR)
- CRDF 0.24
- TLSI 0.34
- MACD
- CRDF 0.03
- TLSI 0.03
- Stochastic Oscillator
- CRDF 56.98
- TLSI 92.94
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.